- Home
- ZNTL vs HCAI Comparison
ZNTL vs HCAI Comparison
Compare ZNTL & HCAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- HCAI
- Stock Information
- Founded
- ZNTL 2014
- HCAI 2004
- Country
- ZNTL United States
- HCAI China
- Employees
- ZNTL N/A
- HCAI N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- HCAI Miscellaneous manufacturing industries
- Sector
- ZNTL Health Care
- HCAI Consumer Discretionary
- Exchange
- ZNTL Nasdaq
- HCAI Nasdaq
- Market Cap
- ZNTL 134.7M
- HCAI 161.3M
- IPO Year
- ZNTL 2020
- HCAI 2025
- Fundamental
- Price
- ZNTL $2.32
- HCAI $3.95
- Analyst Decision
- ZNTL Buy
- HCAI
- Analyst Count
- ZNTL 8
- HCAI 0
- Target Price
- ZNTL $8.53
- HCAI N/A
- AVG Volume (30 Days)
- ZNTL 2.7M
- HCAI 526.0K
- Earning Date
- ZNTL 03-04-2025
- HCAI 01-01-0001
- Dividend Yield
- ZNTL N/A
- HCAI N/A
- EPS Growth
- ZNTL N/A
- HCAI N/A
- EPS
- ZNTL N/A
- HCAI 0.11
- Revenue
- ZNTL $40,560,000.00
- HCAI $53,677,586.00
- Revenue This Year
- ZNTL N/A
- HCAI N/A
- Revenue Next Year
- ZNTL N/A
- HCAI N/A
- P/E Ratio
- ZNTL N/A
- HCAI $37.24
- Revenue Growth
- ZNTL N/A
- HCAI 534.84
- 52 Week Low
- ZNTL $1.61
- HCAI $3.70
- 52 Week High
- ZNTL $18.07
- HCAI $5.32
- Technical
- Relative Strength Index (RSI)
- ZNTL 49.24
- HCAI N/A
- Support Level
- ZNTL $2.37
- HCAI N/A
- Resistance Level
- ZNTL $2.36
- HCAI N/A
- Average True Range (ATR)
- ZNTL 0.25
- HCAI 0.00
- MACD
- ZNTL 0.08
- HCAI 0.00
- Stochastic Oscillator
- ZNTL 69.27
- HCAI 0.00
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About HCAI Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares
Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider.